132 completed, 36 terminated, 6 active not recruiting, 5 withdrawn. 106 Phase 1, 82 Phase 2, 13 Not applicable, 4 Phase 3.
Follow Recurrent Adult Acute Myeloid Leukemia: new trials by email Literature Review of Recurrent Adult Acute Myeloid Leukemia trials Research Report on Recurrent Adult Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML CMGV - Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome | Not applicable | Recruiting | Ruijin Hospital | 78 | 2024-02-03 | 2024-03-26 |
| CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia Anti-CD33 CAR T-cells, Lymphodepletion Therapy - Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 27 | 2023-12-07 | 2026-03-05 |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis - Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Terminated | Sumithira Vasu | 4 | 2020-01-10 | 2025-05-21 |
| Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Laboratory Biomarker Analysis, Nintedanib - Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement | Phase 1 | Active not recruiting | Northwestern University | 44 | 2018-11-14 | 2025-10-21 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine Phosphate - CNS 2a, CNS 2b | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2017-05-25 | 2017-05-03 | |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q) | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-05 | 2019-09-06 |
| Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | Completed | Wake Forest University Health Sciences | 14 | 2017-04-21 | 2022-10-20 | |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Azacitidine, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | University of Southern California | 7 | 2017-04-20 | 2026-06-08 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Cladribine, Cytarabine, Decitabine - Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 28 | 2016-11-17 | 2020-03-17 |
| Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Ibrutinib, Idarubicin - Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Terminated | Steven E. Coutre | 2 | 2016-11-01 | 2018-05-14 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-07-30 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil - Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome | Phase 1 | Terminated | Stanford University | 1 | 2016-02-01 | 2018-09-12 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Pacritinib, Cytarabine, Daunorubicin Hydrochloride - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 13 | 2016-01-12 | 2019-01-25 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis - Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2015-12-15 | 2026-08-26 |
| Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Sirolimus, Mitoxantrone, Etoposide - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 39 | 2015-10-07 | 2026-05-29 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies radiation therapy, cyclophosphamide, anti-thymocyte globulin - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 1 | Completed | Sumithira Vasu | 33 | 2015-07-27 | 2023-09-21 |
Showing 20 of 186. Sign in to see all of them.
Leukemia, Myeloid, Acute (186) · Congenital Abnormalities (111) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (81) · Leukemia, Myelomonocytic, Chronic (53) · Leukemia, Myelomonocytic, Acute (52) · Blast Crisis (49) · Leukemia, Erythroblastic, Acute (47) · Leukemia, Monocytic, Acute (47) · Leukemia, Megakaryoblastic, Acute (46) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Lymphoma, Non-Hodgkin (40) · Hodgkin Disease (38) · Lymphoma, Follicular (37) · Lymphoma, B-Cell, Marginal Zone (36) · Burkitt Lymphoma (35)
Hematologic Diseases (186) · Hemic and Lymphatic Diseases (186) · Neoplasms by Histologic Type (186) · Leukemia (184) · Leukemia, Myeloid (184) · Neoplasms (184) · Bone Marrow Diseases (128) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (111) · Pathologic Processes (100) · Pathological Conditions, Signs and Symptoms (100) · Disease Attributes (98) · Chronic Disease (97) · Immune System Diseases (86) · Immunoproliferative Disorders (86) · Lymphatic Diseases (86)
Cytarabine (44) · fludarabine phosphate (35) · Peripheral Blood Stem Cell Transplantation (32) · Whole-Body Irradiation (27) · Mycophenolic Acid (25) · Mitoxantrone (19) · Tacrolimus (19) · Cyclophosphamide (18) · Cyclosporine (18) · Decitabine (18) · Etoposide (16) · Azacitidine (15) · Busulfan (15) · Methotrexate (11) · merphos (11)
National Cancer Institute (NCI) (67) · Fred Hutchinson Cancer Center (37) · City of Hope Medical Center (10) · Roswell Park Cancer Institute (8) · Wake Forest University Health Sciences (8) · Case Comprehensive Cancer Center (4) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · Stanford University (3) · Sumithira Vasu (3) · University of Chicago (3) · University of Southern California (3) · University of Washington (3) · Alison Walker (2)
United States (176) · Italy (9) · Germany (8) · Canada (6) · China (2) · Israel (2) · Australia (1) · Belgium (1) · Denmark (1) · France (1) · New Zealand (1) · Peru (1) · Puerto Rico (1) · Spain (1)
Brenda Sandmaier (9) · B. Smith (5) · Olatoyosi Odenike (5) · Roland Walter (5) · Francis Giles (4) · Jorge Cortes (4) · Bruno de Medeiros (3) · David Maloney (3) · Pamela Becker (3) · Paul Martin (3) · Timothy Pardee (3) · William Blum (3) · Alison Walker, MD (2) · Anjali Advani (2) · Anthony Stein (2)
PMID 32499241, PMID 23660685, PMID 26577691, PMID 17679729, PMID 18974373, PMID 19546476, PMID 19652201, PMID 19786617, PMID 19794082, PMID 19900571, PMID 20460644, PMID 20952518, PMID 21239698, PMID 21791475, PMID 22259028, PMID 22566605, PMID 22801963, PMID 23256542, PMID 23443507, PMID 24142996, PMID 24178622, PMID 24369094, PMID 24474568, PMID 24583795, PMID 25085357, PMID 26764356, PMID 26784138, PMID 26853648, PMID 26943915, PMID 27374466, PMID 28817727, PMID 29042364, PMID 29567781, PMID 29572391, PMID 30562587, PMID 31212080, PMID 31235963, PMID 31582553, PMID 31688884, PMID 32074275, PMID 32077361, PMID 32211336, PMID 32628342, PMID 32683127, PMID 32777116, PMID 33420905, PMID 34400362, PMID 35007144, PMID 35175355, PMID 35354808
P30CA015704 (26), P01CA018029 (12), U01CA070095 (10), U01CA076576 (10), U01CA062461 (7), P01CA078902 (5), P30CA006973 (5), P30CA012197 (5), P30CA016058 (5), P01HL036444 (4), P30CA015083 (4), P30CA124435 (4), U01CA062491 (4), U01CA062505 (4), N01CM62201 (3)